Abstract Library

#1891 GSK3: A Novel Therapeutic Target in NETs?

Introduction: GSK3 is a serine/threonine-kinase that plays a critical role in cancer. In neuroendocrine tumours (NETs) GSK3 is regularly overactivated.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Nölting S

Authors: Weis C, Aristizabal Prada E, Maurer J, Spöttl G, Grossman A,

Keywords: GSK3-inhibition, neuroendocrine tumors, combination treatment,

#874 The pan-TRK Inhibitor GNF5837 Inhibits Cell Viability and Akt and MAPK Signaling in Human Neuroendocrine GOT1 Tumor Cells

Introduction: The tropomyosin receptor kinase family (TRKA, TRKB, TRKC) effects tumor cell growth in various models. Recent preclinical studies in neuroendocrine carcinoma of the lung cell lines have shown that Trk receptors might be a therapeutic target for neuroendocrine neoplasias.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Heinzle V, Reuther C, Spöttl G, Maurer J, Göke B,

Keywords: neuroendocrine tumor, trk receptor,

#739 Aspirin Inhibits Cell Viability and mTOR Signalling in Neuroendocrine Tumor Cells

Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as thymic and bronchus carcinoids. Aspirin has been reported to inhibit mTOR signalling and exhibit antitumoral activity in colorectal cancer cells. So far, no data with aspirin on NETs have been published.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Spampatti M, Vlotides G, Spöttl G, Maurer J, Göke B,

Keywords: neuroendocrine tumor, MEN-1, aspirin, mTOR,